MyRisk® Hereditary Cancer Test
Use
The MyRisk Test evaluates 63 clinically recommended genes grounded in strong clinical evidence to reveal hereditary cancer risks and treatment-impacting variants across more than 11 cancer types, empowering you to personalize care plans with confidence.
Special Instructions
Inform treatment decisions right from diagnosis The MyRisk Test provides you with more critical answers for more patients by definitively classifying up to 63% of variants that other labs could not.4 Unlock targeted therapy opportunities Did you know that up to 10% of germline variants are missed by tumor testing alone?2 The MyRisk Test identifies germline BRCA1/2 variants that may impact use of targeted therapies such as PARP inhibitors.5,6 Identify risk of secondary cancer and personalize management The MyRisk Test identifies hereditary cancer syndromes associated with a risk for secondary cancers, directly impacting treatment decisions to reduce the occurrence of subsequent cancer.
Limitations
See documentation for test limitations
FDA ApprovedNew York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
7-14 days
Related Documents
Not provided.
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Patient Preparation
Do not eat, drink, smoke, or chew gum 30 min prior to saliva sample collection
Causes for Rejection
Frozen whole blood; serum; leaking tube; clotted blood; grossly hemolyzed specimen; incorrect anticoagulant; saliva collection in incorrect container.